Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016

Enno Schmidt, Volker Spindler, Rüdiger Eming, Masayuki Amagai, Frank Antonicelli, John F. Baines, Meriem Belheouane, Philippe Bernard, Luca Borradori, Marzia Caproni, Giovanni Di Zenzo, Sergei Grando, Karen Harman, Marcel F. Jonkman, Hiroshi Koga, Ralf J. Ludwig, Andrew P. Kowalczyk, Eliane J. Müller, Wataru Nishie, Hendri Pas & 12 others Aimee S. Payne, Christian D. Sadik, Allan Seppänen, Jane Setterfield, Hiroshi Shimizu, Animesh A. Sinha, Eli Sprecher, Michael Sticherling, Hideyuki Ujiie, Detlef Zillikens, Michael Hertl, Jens Waschke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphigoid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can now be achieved using standardized and widely available serological test systems. Various experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction. Major steps were taken to put the various partly contradictory and controversial findings about the effects of pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.

Original languageEnglish
Pages (from-to)1199-1203
Number of pages5
JournalJournal of Investigative Dermatology
Volume137
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Bullous Pemphigoid
Pemphigus
Autoantibodies
Autoimmune Diseases
Central Tolerance
Type 4 Cyclic Nucleotide Phosphodiesterase
Dipeptidyl-Peptidase IV Inhibitors
Peripheral Tolerance
Dermatitis Herpetiformis
Dapsone
Dermatitis
Dermatology
Cytology
Leukotriene B4
Doxycycline
Serologic Tests
Signal transduction
T-Cell Antigen Receptor
Keratinocytes
Cell Adhesion

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. / Schmidt, Enno; Spindler, Volker; Eming, Rüdiger; Amagai, Masayuki; Antonicelli, Frank; Baines, John F.; Belheouane, Meriem; Bernard, Philippe; Borradori, Luca; Caproni, Marzia; Di Zenzo, Giovanni; Grando, Sergei; Harman, Karen; Jonkman, Marcel F.; Koga, Hiroshi; Ludwig, Ralf J.; Kowalczyk, Andrew P.; Müller, Eliane J.; Nishie, Wataru; Pas, Hendri; Payne, Aimee S.; Sadik, Christian D.; Seppänen, Allan; Setterfield, Jane; Shimizu, Hiroshi; Sinha, Animesh A.; Sprecher, Eli; Sticherling, Michael; Ujiie, Hideyuki; Zillikens, Detlef; Hertl, Michael; Waschke, Jens.

In: Journal of Investigative Dermatology, Vol. 137, No. 6, 01.06.2017, p. 1199-1203.

Research output: Contribution to journalArticle

Schmidt, E, Spindler, V, Eming, R, Amagai, M, Antonicelli, F, Baines, JF, Belheouane, M, Bernard, P, Borradori, L, Caproni, M, Di Zenzo, G, Grando, S, Harman, K, Jonkman, MF, Koga, H, Ludwig, RJ, Kowalczyk, AP, Müller, EJ, Nishie, W, Pas, H, Payne, AS, Sadik, CD, Seppänen, A, Setterfield, J, Shimizu, H, Sinha, AA, Sprecher, E, Sticherling, M, Ujiie, H, Zillikens, D, Hertl, M & Waschke, J 2017, 'Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016', Journal of Investigative Dermatology, vol. 137, no. 6, pp. 1199-1203. https://doi.org/10.1016/j.jid.2017.01.028
Schmidt, Enno ; Spindler, Volker ; Eming, Rüdiger ; Amagai, Masayuki ; Antonicelli, Frank ; Baines, John F. ; Belheouane, Meriem ; Bernard, Philippe ; Borradori, Luca ; Caproni, Marzia ; Di Zenzo, Giovanni ; Grando, Sergei ; Harman, Karen ; Jonkman, Marcel F. ; Koga, Hiroshi ; Ludwig, Ralf J. ; Kowalczyk, Andrew P. ; Müller, Eliane J. ; Nishie, Wataru ; Pas, Hendri ; Payne, Aimee S. ; Sadik, Christian D. ; Seppänen, Allan ; Setterfield, Jane ; Shimizu, Hiroshi ; Sinha, Animesh A. ; Sprecher, Eli ; Sticherling, Michael ; Ujiie, Hideyuki ; Zillikens, Detlef ; Hertl, Michael ; Waschke, Jens. / Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. In: Journal of Investigative Dermatology. 2017 ; Vol. 137, No. 6. pp. 1199-1203.
@article{c6708feb084b4b9285ee6e3fe9f7c405,
title = "Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016",
abstract = "Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in L{\"u}beck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphigoid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can now be achieved using standardized and widely available serological test systems. Various experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction. Major steps were taken to put the various partly contradictory and controversial findings about the effects of pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.",
author = "Enno Schmidt and Volker Spindler and R{\"u}diger Eming and Masayuki Amagai and Frank Antonicelli and Baines, {John F.} and Meriem Belheouane and Philippe Bernard and Luca Borradori and Marzia Caproni and {Di Zenzo}, Giovanni and Sergei Grando and Karen Harman and Jonkman, {Marcel F.} and Hiroshi Koga and Ludwig, {Ralf J.} and Kowalczyk, {Andrew P.} and M{\"u}ller, {Eliane J.} and Wataru Nishie and Hendri Pas and Payne, {Aimee S.} and Sadik, {Christian D.} and Allan Sepp{\"a}nen and Jane Setterfield and Hiroshi Shimizu and Sinha, {Animesh A.} and Eli Sprecher and Michael Sticherling and Hideyuki Ujiie and Detlef Zillikens and Michael Hertl and Jens Waschke",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.jid.2017.01.028",
language = "English",
volume = "137",
pages = "1199--1203",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016

AU - Schmidt, Enno

AU - Spindler, Volker

AU - Eming, Rüdiger

AU - Amagai, Masayuki

AU - Antonicelli, Frank

AU - Baines, John F.

AU - Belheouane, Meriem

AU - Bernard, Philippe

AU - Borradori, Luca

AU - Caproni, Marzia

AU - Di Zenzo, Giovanni

AU - Grando, Sergei

AU - Harman, Karen

AU - Jonkman, Marcel F.

AU - Koga, Hiroshi

AU - Ludwig, Ralf J.

AU - Kowalczyk, Andrew P.

AU - Müller, Eliane J.

AU - Nishie, Wataru

AU - Pas, Hendri

AU - Payne, Aimee S.

AU - Sadik, Christian D.

AU - Seppänen, Allan

AU - Setterfield, Jane

AU - Shimizu, Hiroshi

AU - Sinha, Animesh A.

AU - Sprecher, Eli

AU - Sticherling, Michael

AU - Ujiie, Hideyuki

AU - Zillikens, Detlef

AU - Hertl, Michael

AU - Waschke, Jens

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphigoid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can now be achieved using standardized and widely available serological test systems. Various experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction. Major steps were taken to put the various partly contradictory and controversial findings about the effects of pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.

AB - Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphigoid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can now be achieved using standardized and widely available serological test systems. Various experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction. Major steps were taken to put the various partly contradictory and controversial findings about the effects of pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.

UR - http://www.scopus.com/inward/record.url?scp=85019921840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019921840&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2017.01.028

DO - 10.1016/j.jid.2017.01.028

M3 - Article

VL - 137

SP - 1199

EP - 1203

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 6

ER -